Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

Inhibrx, a biotech company based in San Diego, has reported promising results from a combination therapy involving its experimental drug INBRX-106 and Merck's Keytruda. In clinical trials for difficult-to-treat metastatic head and neck cancer, this combination therapy demonstrated a greater tumor shrinkage compared to Keytruda used alone, suggesting a potential advancement in cancer treatment options.